Increasing The Genetic Admixture of Available Lines of Human Pluripotent Stem Cells

Author(s):Show less -

Tofoli, Fabiano A. ; Dasso, Maximiliano ; Morato-Marques, Mariana ; Nunes, Kelly ; Pereira, Lucas Assis ; da Silva, Giselle Siqueira ; Fonseca, Simone A. S. ; Costas, Roberta Montero ; Santos, Hadassa Campos ; Pereira, Alexandre da Costa ; Lotufo, Paulo A. ; Bensenor, Isabela M. ; Meyer, Diogo ; Pereira, Lygia Veiga

• Document type: Journal article
• Source: SCIENTIFIC REPORTS; v. 6, OCT 6 2016.
• Web of Science Citations: 2

Abstract

Human pluripotent stem cells (hPSCs) may significantly improve drug development pipeline, serving as an in vitro system for the identification of novel leads, and for testing drug toxicity. Furthermore, these cells may be used to address the issue of differential drug response, a phenomenon greatly influenced by genetic factors. This application depends on the availability of hPSC lines from populations with diverse ancestries. So far, it has been reported that most lines of hPSCs derived worldwide are of European or East Asian ancestries. We have established 23 lines of hPSCs from Brazilian individuals, and we report the analysis of their genomic ancestry. We show that embryo-derived PSCs are mostly of European descent, while induced PSCs derived from participants of a national-wide Brazilian cohort study present high levels of admixed European, African and Native American genomic ancestry. Additionally, we use high density SNP data and estimate local ancestries, particularly those of CYP genes loci. Such information will be of key importance when interpreting variation among cell lines with respect to cellular phenotypes of interest. The availability of genetically admixed lines of hPSCs will be of relevance when setting up future in vitro studies of drug response. (AU)

• FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
• Grantee: Dimas Tadeu Covas
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC